In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Alvogen, Inc.

http://www.alvogen.com

Latest From Alvogen, Inc.

Adalvo Files For Generic Version Of Takeda’s Firazyr

Alvogen’s newly created B2B unit, Adalvo, has filed for a generic version of Takeda’s Firazyr with the EMA to enhace its peptide portfolio, which currently includes several products focused on rare diseases and diabetes. Adalvo believes it is in the first wave of applicants to submit its filing within the European Union.

Generic Drugs Strategy

Pfenex And Alvogen Forsteo Biosimilars Primed For EU Market

Shortly after announcing the launch of Bonsity (teriparatide) in the US, Pfenex and Alvogen have picked up positive opinions from the EMA’s CHMP for their teriparatide biosimilar. However, Accord Healthcare has withdrawn its own application following concerns raised by the agency.

Biosimilars Regulation

Pfenex And Alvogen Launch US Teriparatide

Pfenex marketing partner Alvogen has introduced the firm’s Bonsity version of teriparatide in the US. Representing the first Pfenex-developed product to hit the market, the launch comes as the companies are still awaiting a formal equivalence designation from the FDA.

Launches United States

Alvogen Group Unveils Adalvo B2B Unit

The Alvogen group of companies has unveiled Adalvo as the new identity for its B2B unit. In an exclusive interview, general manager Anil Okay talks about the reasons behind the rebranding, what makes it unique in the B2B sphere and the significance of 2023 for Adalvo’s strategy.

Business Strategies Commercial
See All

Company Information

  • Industry
  • Contract Research, Toxicology Testing-CRO
  • Distributors
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
  • Other Names / Subsidiaries
    • Alvogen Korea Co., Ltd, Lotus Pharmaceuticals
UsernamePublicRestriction

Register